Tag: Weight Loss
Amid Shortages, Maker Says Restrictions on Wegovy Will Continue Into 2024
Based on body mass index, 120 million Americans would qualify to take Wegovy
Odds of Clinically Meaningful Weight Loss Low in Adults With Overweight, Obesity
Despite fewer than one in 10 achieving it, likelihood of ≥5 percent weight loss was higher than reaching healthy weight body mass index category
Wegovy Lowered Users’ Heart Risks in New Trial
Clinical trial demonstrates reduction in major adverse cardiovascular events of 20 percent, drug maker says
Lawsuit Against Makers of Ozempic, Mounjaro Claim Meds Caused ‘Stomach Paralysis’
Lawsuit alleges drugmakers failed to adequately warn patients about the risk for severe stomach problems
Time-Restricted Eating May Aid Weight Loss With Type 2 Diabetes
No change in cardiometabolic risk factors or glycemic control seen over six months
European Regulators Investigating Risk for Suicidal Thoughts With Popular Weight-Loss Drugs
Three case reports from Iceland spurred the review; two of the cases involved Ozempic
ADA: Reductions in Body Weight With Retatrutide for Obesity
Substantial reductions seen in body weight with retatrutide treatment for 48 weeks in phase 2 trial
ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
Substantial and clinically meaningful reductions in body weight seen for adults with obesity and type 2 diabetes
ADA: Once-Daily Semaglutide Superior for Reduction in Body Weight
Superior and clinically meaningful reduction in body weight in adults with overweight, obesity without type 2 diabetes
ADA: Once-Daily Orforglipron Linked to Significant Weight Reduction
Weight reduction of at least 10 percent occurred in 46 to 75 percent receiving orforglipron by week 36